Evidence map›Paper›PMID 42533550›Full record

ArticlemAbs2026

Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies.

Santosh Kumar Paidi, Julissa Ibrahim, Kateryna Stepurska, Jonathan Zarzar, Saeed Izadi, Erina Rude, Steven Luu, Daniel Kovner, Kelly O'Connor, Karenna Bol and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Santosh Kumar PaidiAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.ORCID 0000-0002-7034-586X
Julissa IbrahimAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.
Kateryna StepurskaAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.
Jonathan ZarzarPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Saeed IzadiPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.ORCID 0000-0003-4206-8559
Erina RudePharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Steven LuuPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Daniel KovnerPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Kelly O'ConnorPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Karenna BolAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.
Shrenik MehtaPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Nisana AndersenAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.
Nicole StephensAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.
Emily MakowskiAntibody Engineering, Genentech, Inc., South San Francisco, CA, USA.
Joel HeislerAntibody Engineering, Genentech, Inc., South San Francisco, CA, USA.
Trevor SwartzPharmaceutical Development, Genentech, Inc., South San Francisco, CA, USA.
Paul J CarterAntibody Engineering, Genentech, Inc., South San Francisco, CA, USA.
Tomasz BaginskiAnalytical Development, Genentech, Inc., South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting high-concentration viscosity of monoclonal antibodies is crucial for their development as therapeutics for subcutaneous delivery, but traditional experimental rheometry methods for assessing viscosity are low-throughput, which limits their utility. This study evaluates self-interaction nanoparticle spectroscopy (SINS) assays - specifically charge-stabilized SINS (CS-SINS) and PEG-stabilized SINS (PS-SINS) - for high-throughput viscosity prediction. We characterized 96 IgG

Indexed as

Antibodies, MonoclonalImmunoglobulin GNanoparticlesSpectrum AnalysisHumansViscosityAntibodies, MonoclonalImmunoglobulin Gantibody screeningantibody viscosityCS-SINSdevelopabilityin silicomachine learningmolecular descriptorsPS-SINSSelf-interaction nanoparticle spectroscopy (SINS)

Identifiers

PMID42533550
PMCPMC13432892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.